Study in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)

This study tests a new investigational drug in people with heart failure with preserved ejection fraction (HFpEF) — a form of heart failure where the heart muscle contracts normally but is too stiff, making it harder for the heart to fill with blood properly. **You may be eligible if...** - You have been diagnosed with stable heart failure (NYHA class II or III) for at least 6 months - Your heart's pumping function is 50% or above (preserved ejection fraction) - You have objective evidence of heart failure documented in your medical records - You have been on stable heart failure medications for at least 30 days **You may NOT be eligible if...** - You have hypertrophic cardiomyopathy or a storage disorder like amyloidosis or Fabry disease - You have uncontrolled or persistent atrial fibrillation without adequate blood thinning treatment - You are participating in another clinical drug study - You have a psychiatric condition that would prevent you from giving consent Talk to your doctor to see if this trial is right for you.